Finalist
Innovative Medical Education for an Asset in Life Cycle Management: Engaging HCPs Through Peer-Led Podcast Publications
Summary of work
NSCLC harboring METexon14 skipping has a poor prognosis, and optimal care from the start of treatment is essential. Targeted treatment options have been available for nearly four years – but questions remain unanswered. To help address frequent queries on biomarker testing and optimal sequencing of targeted therapies, Syneos Health Communications partnered with EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, to develop an innovative series of two peer-reviewed podcast manuscripts published in Advances in Therapy. This novel format combines expert audio discussions with full transcripts, infographics, and plain-language summaries, meeting the needs of time-pressured HCPs and reinforcing scientific rigour through peer review.By engaging leading oncologists to share evidence-based insights and real-life case studies, the initiative delivered highly accessible education that directly answered practice-relevant questions. There is strong engagement — with over 8,000 unique accesses in just three months for the most recent publication — and enthusiastic KOL support, evidencing how a mature brand can continue to provide meaningful value for clinicians and patients alike.
Judges’ comments
This entry from EMD Serono and Syneos Health had good insight led strategy, aims and informing objectives. It had a logical step wise approach, with good engagements and strong access metrics.
